

**Notice of Conclusion of a Definitive Agreement Regarding  
Co-development and Marketing Collaboration in Japan on Gel-One  
for the Treatment of Osteoarthritis**

Seikagaku Corporation (Tokyo, Japan; “Seikagaku”) today announced that it has entered into a definitive agreement with Ono Pharmaceutical Co., Ltd. (Osaka, Japan; “Ono Pharmaceutical”), based on the discussions held related to co-development and marketing collaboration on Gel One under development by Seikagaku for the treatment of osteoarthritis in Japan, as stated in the press release dated April 25, 2025, “Seikagaku and Ono Reach a Basic Agreement Related to Co-development and Marketing Collaboration on Gel-One for the Treatment of Osteoarthritis in Japan.”

Under the agreement, Ono Pharmaceutical acquires co-development and exclusive marketing rights related to Gel-One in Japan. Seikagaku plans to receive tiered royalties over multiple years from Ono Pharmaceutical in on future progress in development and marketing.

In Japan, three Phase III clinical studies are being conducted, a study for osteoarthritis of the knee, a study for osteoarthritis of the hip, and a long-term safety study for both joints. The companies are committed to facilitating these clinical studies as quickly as possible to obtain an approval for manufacturing and marketing authorization for the product at an earlier date.

The impact of this matter on the forecast of consolidated financial results for the fiscal year ending March 31, 2026 is immaterial. Seikagaku will promptly disclose any matter requiring disclosure that arises in the future.

<Reference Information>

**About Gel-One**

Gel-One is an intra-articular injection whose active ingredient is a cross-linked hyaluronate, utilizing Seikagaku’s unique cross-linking technology. Since Gel-One remains in the joint for a long period of time, a single injection of Gel-One is expected to provide long-term pain relief.

The product has been available in overseas markets since 2012 as Gel-One® (U.S.) and HyLink® (Taiwan and Italy) indicated for osteoarthritis of the knee.

Additionally, whereas the indication for Gel-One in overseas markets is the knee joint, in Japan, Seikagaku is concurrently conducting a study of Gel-One for osteoarthritis of the hip alongside the knee study with the aim of expanding the target patient population.

#####

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.